BIMEKIZUMAB

bimekizumab 160 mg/mL injection, 2 x 1 mL pen devices

BIMEKIZUMAB (15110G)

bimekizumab 160 mg/mL injection, 2 x 1 mL pen devices
15110G
Body System:
Manner of administration:Injection
General Schedule
Authority Required

Restriction

Indication: Moderate to severe hidradenitis suppurativa
Treatment phase: Initial 1 (new patient), Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years), or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 2 Max qty units: 4 # of repeats: 3 DPMQ: $6,682.94 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Bimzelx